NRIX · Nurix Therapeutics, Inc. · Executive Compensation
$23.00
+0.01 (+0.04%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$2.39B
Shares
103.78M
Volume · Oct 2
815.51K
Avg daily vol (3M)
1.26M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $6,374,138 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,498,124 |
| Hans van Houte | Chief Financial Officer | $2,296,503 |
| Christine Ring | Chief Legal Officer and Chief Compliance Officer | $2,263,337 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $5,812,862 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,033,860 |
| Christine Ring | Chief Legal Officer and Chief Compliance Officer | $2,016,484 |
| Hans van Houte | Chief Financial Officer | $2,016,482 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $4,363,120 |
| Gwenn M. Hansen | Chief Scientific Officer | $1,632,757 |
| Hans van Houte | Chief Financial Officer | $1,611,987 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | President, Chief Executive Officer and Director | $9,416,222 |
| Hans van Houte | Chief Financial Officer | $4,307,781 |
| Gwenn M. Hansen | Chief Scientific Officer | $3,824,583 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stefani A. Wolff | Chief Operating Officer and Executive Vice President, Product Development | $7,148,424 |
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $4,791,466 |
| Gwenn M. Hansen | Chief Scientific Officer | $2,303,328 |
| Hans van Houte | Chief Financial Officer | $1,659,957 |
| Christine Ring | Ph.D., J.D. General Counsel and Secretary | $1,648,895 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $16,867,841 |
| Gwenn M. Hansen | Chief Scientific Officer | $1,552,577 |
| Christine Ring | Ph.D., J.D. General Counsel and Secretary | $1,307,091 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Arthur T. Sands | M.D., Ph.D. President, Chief Executive Officer and Director | $1,481,610 |
| Gwenn M. Hansen | Chief Scientific Officer | $695,404 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Dansey, M.D. | director | Appointed | 2025-11-10 |
| Roy D. Baynes, MB.Bch., M.Med., Ph.D. | chair of the Clinical and Commercialization Committee | Appointed | 2025-08-22 |
| Lori A. Kunkel, M.D. | chair of the Clinical and Commercialization Committee | Resigned | 2025-08-22 |
| Lori A. Kunkel, M.D. | Class III director | Resigned | 2025-08-22 |
| Roy D. Baynes, MB.Bch., M.Med., Ph.D. | director | Appointed | 2025-03-13 |
| Anil Kapur | director | Appointed | 2024-10-16 |
| Stefani A. Wolff | Chief Operating Officer and Executive Vice President of Product Development | Resigned | 2023-04-10 |
| Edward C. Saltzman | director | Appointed | 2022-09-14 |